Albemarle Corporation reported its fourth quarter earnings for 2024, revealing net sales of $1.23 billion, which fell short of analysts' expectations of $1.34 billion. The company posted a net income of $75 million, a 112.2% increase year-over-year, translating to earnings of $0.29 per diluted share. However, the adjusted diluted loss per share was reported at ($1.09), significantly worse than the anticipated loss of ($0.70). The company’s adjusted EBITDA stood at $251 million, with year-over-year increases across all business segments. Looking ahead, Albemarle provided guidance for fiscal year 2025, projecting revenues between $4.9 billion and $5.2 billion, below the estimated $5.589 billion. Additionally, Albemarle announced plans to place its Chengdu technical and battery-grade lithium hydroxide site into care and maintenance by mid-2025 and to shift some production at its Qinzhou facility from lithium hydroxide to carbonate.